FILTER

Refine your search with the following facets to narrow down your results.

11 Current news of Transition Therapeutics

Transition Therapeutics Announces Appointment of Vice-President of Clinical Operations

22-Jun-2009 - Transition Therapeutics Inc. announced that Ms. Laura Agensky has been appointed Vice-President of Clinical Operations. Since joining Transition in 2001, Ms. Agensky has managed the execution of all the Company's clinical trials across a diverse set of disease indications including Alzheimer's ...

Alzheimer's disease biotechnology clinical trials +1

Elan and Transition Therapeutics Achieve Patient Enrollment Target in Phase 2 Clinical Study of ELND005 (AZD-103)

22-Oct-2008 - Elan Corporation, plc and Transition Therapeutics Inc. announced the achievement of the patient enrollment target for a Phase 2 clinical study of ELND005 (AZD-103) in patients with Alzheimer's disease. The study is a randomized, double-blind, placebo-controlled, dose-ranging, safety and efficacy ...

Alzheimer's disease

Transition Therapeutics Strengthens Drug Discovery Group

20-Aug-2008 - Transition Therapeutics Inc. announced a series of actions to strengthen the Company's drug discovery group. Transition has acquired certain assets and the exclusive rights to three drug discovery projects from Forbes Medi-Tech (Research) Inc., a wholly owned subsidiary of Forbes Medi-Tech Inc. ...

biotechnology

Transition Therapeutics Announces Completion of Phase I Clinical Studies with Alzheimer's Disease Drug Candidate

31-Aug-2007 - Transition Therapeutics Inc. announced the completion of Phase I clinical studies with Alzheimer's disease drug candidate ELND-005/AZD-103. Transition and its development partner Elan Corporation, plc. have performed multiple Phase I studies evaluating the safety, tolerability and pharmacokinetic ...

Alzheimer's disease clinical trials dosing +3

Transition Therapeutics Acquires All Remaining Shares of NeuroMedix Inc.

05-Jun-2007 - Transition Therapeutics Inc. announced that Transition has acquired all of the remaining outstanding common shares of NeuroMedix Inc. pursuant to the compulsory acquisition provisions of the Business Corporations Act (Ontario). Transition now beneficially owns 100% of the common shares of ...

Transition Therapeutics Completes Tender Offer for CNS-Focused NeuroMedix Inc.

14-May-2007 - Transition Therapeutics Inc. and NeuroMedix Inc. announced the successful completion of Transition's tender offer for the outstanding shares of NeuroMedix, a central nervous system ("CNS") focused biotechnology company. According to the company, NeuroMedix's lead compound, Minozac, has the key ...

Alzheimer's disease central nervous system CNS drugs

FDA Grants Fast Track Designation to Alzheimer's Disease Drug Candidate AZD-103/ELND005

10-Apr-2007 - Transition Therapeutics Inc. announced that the United States Food and Drug Administration has granted Fast Track designation to investigational drug candidate AZD-103/ELND005, being developed in collaboration with Elan Corporation, plc. for the treatment of Alzheimer's disease. AZD-103/ELND005 ...

Alzheimer's disease clinical trials food

Transition Therapeutics Inc. Builds on Its CNS Franchise with the Acquisition of NeuroMedix Inc.

23-Mar-2007 - Transition Therapeutics Inc. announced that it has signed an agreement to offer to purchase all of the outstanding shares of NeuroMedix Inc, a central nervous system ("CNS") focused biopharmaceutical company. NeuroMedix is developing a series of compounds that have been shown to improve cognitive ...

Alzheimer's disease central nervous system CNS drugs +1

Elan and Transition Therapeutics Inc. Announce Global Collaboration to Develop and Commercialize Alzheimer's Disease Drug AZD-10

04-Oct-2006 - Elan Corporation, plc and Transition Therapeutics Inc. announced an exclusive, worldwide collaboration agreement for the joint development and commercialization of a novel therapeutic agent, AZD-103, for the treatment of Alzheimer's disease. AZD-103 is a small molecule compound in Phase I ...

Alzheimer's disease milestone payments pathology +1

Positive Preclinical Data with Transition Therapeutics Alzheimer's Disease Drug Candidate AZD-103

14-Jun-2006 - Transition Therapeutics Inc. announced that Nature Medicine has published an online version of a publication of preclinical studies with Transition's lead Alzheimer's disease drug candidate, AZD-103. The AZD-103 compound is a possible disease-modifying therapeutic drug candidate for the treatment ...

Alzheimer's disease drug development medicine +1